Lets check on where stocks are diverging with Abigail Doolittle. Abigail we have a big divergent , one that is rolling as the day goes on. We have the dow, the s p 500 trading modestly lower, the dow down about. 3 , the s p 500 about 2 . 2 being dragged down by energy, look at the nasdaq. , andasdaq up about. 5 tech is helping, one of the only two sectors positive in the s p 500, but biotech is as well, pretty investing there. Oil is the big story after what could have been perceived as somewhat of a bullish department of Energy Inventories report. According to our oriole strategist at bloomberg, oil is down 3 , now down 23 from the february peak. Energy is the worst sector for the s p 500. These are among the worst performers. Chesapeake, apache, transocean. When we look at the bloomberg chart, thisthis will not come as a surprise either. We have the s p 500 energy index being taken down, and below we have percentage of energy to the s p 500. Right now, it is at the lowest level since
Lets check on where stocks are diverging with Abigail Doolittle. Abigail we have a big divergent , one that is rolling as the day goes on. We have the dow, the s p 500 trading modestly lower, the dow down about. 3 , the s p 500 about 2 . 2 being dragged down by energy, look at the nasdaq. , andasdaq up about. 5 tech is helping, one of the only two sectors positive in the s p 500, but biotech is as well, pretty investing there. Oil is the big story after what could have been perceived as somewhat of a bullish department of Energy Inventories report. According to our oriole strategist at bloomberg, oil is down 3 , now down 23 from the february peak. Energy is the worst sector for the s p 500. These are among the worst performers. Chesapeake, apache, transocean. When we look at the bloomberg chart, thisthis will not come as a surprise either. We have the s p 500 energy index being taken down, and below we have percentage of energy to the s p 500. Right now, it is at the lowest level since
Consensus among the speakers that future Business Needs to be done on a different basis. And and that part of this introspection process is looking ahead with that in mind. Could we get a little more particular around, a little more concrete into what actually would you see as the essential changes in practices, in coordinating mechanisms, in planning and creating incentives . Julie. One thing i think we would all agree on is that companies crave predictability. So we would like to have the i confidence that if we start something, we can move it to completion. We would like to have the confidence that, for example, if we have a government partnership, that partnership is good for the duration of whatever does were trying to do and that something is going going to go away with the next election or the next sequestration of the next challenging circumstances in anybodys government. I think thats one aspect of it is come under the confidence that if were going to make an investment in the
Probably get an answer of efficacy more quickly. Once you get the efficacy you we will distribute that vaccine to everybody and anybody who might benefit. Ultimately if ultimately if it works everyone we will get. That is the framework. Then we look at the advantages and disadvantages if you are distributing a vaccine before you no it works for the advantages if it does work you get it to people quickly. The disadvantage is you may not ever prove that it does work. The inevitable next outbreak we wont no if we have a vaccine that works. The issue with the randomized controlled placebo trial as some people are not getting it right away. Away. There is an absolute understandable desire that if something will be beneficial get it their as quickly as possible. I will finish with this. I mentioned this at another seminar about the issue of the difference between therapies you make readily available for which i was the champion versus a vaccine that you dont know works. And there is big diff
Number three share some future looking ideas on how we can be better prepared in the future to handle situations like these and then i would be happy to discuss these will pocket into the qanda part. The phase one trial which has been completed and published satisfactory we also have the enrolled in cities in the uk, switzerland and then molly. I say this with precision because our perspective is that we need to define what is the best storage to use in phase two. We also are planning on starting to trials in africa when including almost 3,000 subjects and the other involving about 800 in the middle of january and then the phase three where we have a commitment with the nih to purchase a piece participate in the trial and see the leone. That is what we have planned and we also have tuesday and we can only have a good vaccine that can protect in the short term but have a sustained longrange by providing the booster vaccine by combining the vaccines that we are developing. So quite a com